S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:AVRO

AVROBIO (AVRO) Stock Price, News & Analysis

$1.28
+0.02 (+1.59%)
(As of 03/28/2024 ET)
Today's Range
$1.25
$1.30
50-Day Range
$1.15
$1.37
52-Week Range
$0.57
$1.70
Volume
104,197 shs
Average Volume
317,367 shs
Market Capitalization
$57.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

AVROBIO MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
56.3% Upside
$2.00 Price Target
Short Interest
Healthy
0.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of AVROBIO in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.58 to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

Medical Sector

595th out of 938 stocks

Biological Products, Except Diagnostic Industry

96th out of 148 stocks

AVRO stock logo

About AVROBIO Stock (NASDAQ:AVRO)

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVRO Stock Price History

AVRO Stock News Headlines

AVROBIO Inc.
AVRO Apr 2024 2.500 call
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
AVRO May 2024 2.500 call
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
AVROBIO and Tectonic Therapeutic Announce Merger
Mizuho Downgrades AVROBIO (AVRO)
Avrobio just downgraded at Mizuho, here's why
Avrobio Inc AVRO
AVROBIO, Inc. (AVRO)
Avrobio (AVRO) Gets a Buy from Barclays
See More Headlines
Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+56.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$12.16 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.29 per share
Book Value
$2.13 per share

Miscellaneous

Free Float
40,734,000
Market Cap
$57.42 million
Optionable
Optionable
Beta
1.24
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Erik John Ostrowski M.B.A. (Age 52)
    President, Interim CEO, CFO & Treasurer
    Comp: $1.25M
  • Dr. Azadeh Golipour Ph.D. (Age 44)
    Chief Technology Officer
    Comp: $1.01M
  • Dr. Essra Ridha FFPM (Age 41)
    M.D., Chief Medical Officer
    Comp: $1.12M
  • Mr. Jeffrey Medin Ph.D.
    Scientific Founder
  • Mr. Steven N. Avruch J.D. (Age 62)
    Chief Legal Officer & Secretary
    Comp: $506.68k
  • Mr. Scott Gottesman
    Vice President of Human Resource
  • Ms. Kirsten Dupuis
    Chief of Staff

AVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVRO, but not buy additional shares or sell existing shares.
View AVRO analyst ratings
or view top-rated stocks.

What is AVROBIO's stock price target for 2024?

2 brokers have issued 1-year price targets for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price.
View analysts price targets for AVRO
or view top-rated stocks among Wall Street analysts.

How have AVRO shares performed in 2024?

AVROBIO's stock was trading at $1.36 at the beginning of the year. Since then, AVRO stock has decreased by 5.9% and is now trading at $1.28.
View the best growth stocks for 2024 here
.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.75) EPS for the quarter, hitting analysts' consensus estimates of ($0.75).

What other stocks do shareholders of AVROBIO own?
When did AVROBIO IPO?

AVROBIO (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (6.13%), Vanguard Group Inc. (3.59%), Vanguard Group Inc. (3.59%), Vazirani Asset Management LLC (1.46%), FNY Investment Advisers LLC (0.90%) and GABELLI & Co INVESTMENT ADVISERS INC. (0.79%).
View institutional ownership trends
.

How do I buy shares of AVROBIO?

Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVRO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners